BioFactura Funded $16 Million Contract Option for its Smallpox Biodefense Therapeutic
Frederick, Maryland, October 2, 2023: BioFactura, Inc. today announced a contract option activation...
BioFactura develops and manufactures high-value biosimilars, biodefense medical countermeasures, and client-selected novel drugs..
BioFactura is committed to identifying and fulfilling unmet global biomedical and national biodefense needs..
BioFactura has developed the StableFastTM Biomanufacturing Platform, a novel system to rapidly generate stable..
BioFactura’s biopharmaceutical industry experience is grounded in bioprocess development,scale-up, and manufacturing..
Frederick, Maryland, October 2, 2023: BioFactura, Inc. today announced a contract option activation...
Frederick, Maryland, September 11, 2023: BioFactura, Inc. announced the publication of the phase 1...
Jeffrey N. Hausfeld, Rodeina Challand, Kristi McLendon, Nathaniel Macapagal, Pam Bruce-Staskal, Chri...
Eric M. Mucker, Suzanne E. Wollen-Roberts, Adrienne Kimmel, Josh Shamblin, Darryl Sampey and Jay W....